Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
ALTG Alta Equipment Group Inc
UNP Union Pacific Corp
AHI Advanced Health Intelligence Ltd
EMUSF Electric Metals USA Ltd
INPX Inpixon
HUBC Hub Cyber Security Ltd
PTON Peloton Interactive Inc
PIXY ShiftPixy Inc
BCAN BYND Cannasoft Enterprises Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Longeveron Inc. is a clinical-stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, such as aging related frailty, Alzheimer's disease (AD), acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Day's Change
-0.0597 (-2.63%)
B/A Size
Day's High
Day's Low

Today's volume of 5,453 shares is on pace to be much lighter than LGVN's 10-day average volume of 51,971 shares.


Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants

8:42 am ET May 9, 2023 (MarketWatch)

Longeveron Inc.'s stock (LGVN) rocketed 15.5% in premarket trade Tuesday, after the biotech said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) achieved 100% survival up to 5 years of age in a trial. The trial involved 10 patients who survived and remained transplant-free after receiving Lomecel-B during Stage 2 surgery. All patients were more than 4 years of age and 2 were 5. Additional long-term follow-up is ongoing. "Historical results have shown that children with HLHS have approximately 20% mortality by 5 years," the company said in a statement. The company expects to present the data at a scientific conference later in 2023. HLHS affects about 1,000 babies a year.

-Ciara Linnane

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 09, 2023 08:42 ET (12:42 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.